Emactuzumab - Roche

Drug Profile

Emactuzumab - Roche

Alternative Names: RG-7155; RO-5509554

Latest Information Update: 17 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Roche; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Macrophage colony stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pigmented villonodular synovitis; Giant cell tumour of tendon sheath
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Discontinued Giant cell tumour of tendon sheath; Pigmented villonodular synovitis

Most Recent Events

  • 06 Apr 2018 Roche completes a phase I trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in USA, Belgium, France (IV) (NCT02760797)
  • 07 Feb 2018 Phase-I development is ongoing in Solid-tumours(Late-stage disease, Monotherapy) in USA, France (IV, Infusion)
  • 07 Feb 2018 Roche completes a phase I trial in Solid-tumours (Late-stage disease, Monotherapy, Combination therapy, Metastatic disease) in USA, France (IV, Infusion) (NCT01494688)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top